GlassScriptPhysician profile
Gregory W Melieste
NPI 1396794517
$1,503.00
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $211.39 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $205.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.17 | 2019-2020 | |
| Allergan, INC. | $178.89 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $147.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $119.09 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $91.50 | 2019-2020 | |
| Lundbeck LLC | $75.15 | 2019-2020 | |
| Tris Pharma INC | $70.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $64.14 | 2019 | |
| Vertical Pharmaceuticals, LLC | $49.87 | 2019 | |
| Shire North American Group INC | $34.20 | 2019 | |
| Adlon Therapeutics L.P. | $27.82 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $18.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Melieste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.